Humacyte Phase 3 trial data to be presented at ASN Kidney Week
Tweet Send to a Friend
Humacyte, Inc. (Nasdaq: HUMA) announced that interim results from its V012 Phase 3 clinical trial have been accepted for a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




